Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02349139 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 27 | Asana BioSciencesINDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02606123 |
| Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer |
| terminated |
| Phase 1 / Phase 2 |
| 28 |
| ESSA PharmaceuticalsINDUSTRY |
| 2 |
| Mar 1, 2018 |
| clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT00004261 | EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | terminated | Phase 1 | — | University Health Network, TorontoOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02363855 | Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects | completed | Phase 1 | 9 | BayerINDUSTRY | 1 | Jan 25, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT01949519 | Docetaxel and Lycopene in Metastatic Prostate Cancer | completed | Phase 1 | 24 | Medical University of South CarolinaOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | completed | Phase 1 | 62 | Inovio PharmaceuticalsINDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01085422 | A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer | completed | Phase 1 | 35 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02916537 | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | completed | Phase 1 | 20 | Cancer Targeted TechnologyINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00060528 | Sequential Vaccinations in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02468284 | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | completed | Phase 1 | 15 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01186484 | Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer | completed | Phase 1 | 27 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT02911350 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | completed | Phase 1 | 23 | NYU Langone HealthOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT02654938 | Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer | completed | Phase 1 | 32 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02844699 | A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01677845 | Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer | terminated | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT01832870 | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | completed | Phase 1 | 9 | Prostate Oncology Specialists, Inc.OTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02452307 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 36 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | completed | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 2, 2017 | clinicaltrials |
| NCT01594918 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 25 | Rahul AggarwalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT02225093 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | completed | Phase 1 | 12 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00148928 | Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01642732 | Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer | terminated | Phase 1 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02429804 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03164837 | 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT00959335 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
| NCT00960310 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2018source: clinicaltrials